Sugi Predict

Sugi Predict / Compounds / SCHEMBL255211

SCHEMBL255211

SCHEMBL255211

CC(C)CC[C@H](N)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC1A3 P43003 4/20 0.65
▸ SLC1A2 P43004 4/20 0.65
▸ SLC1A1 P43005 3/20 0.65
▸ SLC7A5 Q01650 1/20 0.61
▸ BHMT Q93088 2/20 0.55
▸ BHMT2 Q9H2M3 1/20 0.55
▸ GSR P00390 2/20 0.54
▸ GRM8 O00222 1/20 0.54
▸ GRM6 O15303 1/20 0.54
▸ GRIN2D O15399 1/20 0.54
▸ GRIN3B O60391 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ GRIK1 P39086 1/20 0.54
▸ GRM5 P41594 1/20 0.54
▸ GRIA1 P42261 1/20 0.54
▸ GRIA2 P42262 1/20 0.54
▸ GRIA3 P42263 1/20 0.54
▸ GRIA4 P48058 1/20 0.54
▸ GRIN1 Q05586 1/20 0.54
▸ GRIN2A Q12879 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1531631 1.00 SLC1A3 (0.65) SLC1A3SLC1A2SLC1A1SLC7A5BHMT
SCHEMBL514816 1.00 SLC1A3 (0.65) SLC1A3SLC1A2SLC1A1SLC7A5BHMT
Hydrochloric Acid SCHEMBL20361640 0.97 SLC1A3 (0.63) SLC1A3SLC1A2SLC1A1SLC7A5BHMT
Hydrochloric Acid SCHEMBL20361639 0.97 SLC1A3 (0.63) SLC1A3SLC1A2SLC1A1SLC7A5BHMT
SCHEMBL602426 0.86 GSR (0.68) SLC1A3SLC1A2SLC1A1SLC7A5BHMT
SCHEMBL8068164 0.86 GSR (0.68) SLC1A3SLC1A2SLC1A1SLC7A5BHMT
SCHEMBL5859579 0.85 GSR (0.64) SLC1A3SLC1A2SLC1A1SLC7A5GSR
SCHEMBL563055 0.85 GSR (0.58) SLC1A3SLC1A2SLC1A1SLC7A5GSR
SCHEMBL564047 0.85 GSR (0.58) SLC1A3SLC1A2SLC1A1SLC7A5GSR
SCHEMBL13343952 0.85 GSR (0.64) SLC1A3SLC1A2SLC1A1SLC7A5GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094701-A TLR3 binding bicyclic peptide ligands — 2026-05-26 — — CN claimed
US-12630588-B2 Bicyclic peptide ligands specific for CD137 BICYCLETX LIMITED (GB) 2026-05-19 — — US claimed
WO-2026099897-A1 NOVEL LINKERS AND ITS PREPARATION METHODS THEREOF ZYDUS LIFESCIENCES LIMITED (IN) 2026-05-15 — — WO claimed
US-12590123-B2 Compounds and methods for treating cancer, viral infections, and allergic conditions WASHINGTON UNIVERSITY (US) 2026-03-31 — — US claimed
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2026-03-26 — — US claimed
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2026-02-17 — — US claimed
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS INC (US) 2026-01-01 — — US claimed
EP-4650362-A1 NEUROPROTECTIVE PSD-95 POLYPEPTIDE INHIBITOR AND USE THEREOF Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) 2025-11-19 — — EP claimed
EP-4633657-A1 STAPLED PEPTIDES AND METHODS THEREOF Parabilis Medicines, Inc. (US) 2025-10-22 — — EP claimed
EP-4633656-A1 STAPLED PEPTIDES AND METHODS THEREOF Parabilis Medicines, Inc. (US) 2025-10-22 — — EP claimed
US-8877738-B2 Antipathogenic peptides SPIDERBIOTECH S.R.L. (IT) 2014-11-04 — — US claimed
US-8466108-B2 TFPI inhibitors and methods of use BAXTER INTERNATIONAL INC. (US) 2013-06-18 — — US claimed
EP-2462155-A1 NOVEL ANTIPATHOGENIC PEPTIDES Spiderbiotech S.r.l. (IT) 2012-06-13 — — EP claimed
US-20120121623-A1 NOVEL ANTIPATHOGENIC PEPTIDES SPIDERBIOTCH S.r.L. (IT) 2012-05-17 — — US claimed
CN-102348462-A Tfpi inhibitors and methods of use BAXTER INT 2012-02-08 — — CN claimed
EP-2379096-A2 TFPI INHIBITORS AND METHODS OF USE Baxter International Inc. (US) 2011-10-26 — — EP claimed
WO-2011015628-A1 NOVEL ANTIPATHOGENIC PEPTIDES SPIDERBIOTECH S.R.L. (IT) 2011-02-10 — — WO claimed
WO-2010071894-A2 TFPI INHIBITORS AND METHODS OF USE BAXTER INTERNATIONAL INC. (US) 2010-06-24 — — WO claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 — — CN claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP SLC1A3 2595/4885SLC1A2 3742/4885SLC1A1 3349/4885
US-12630588-B2 Bicyclic peptide ligands specific for CD137 PTMS, IL36G, HLA-A SLC1A3 345/4885SLC1A2 1147/4885SLC1A1 314/4885
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST MC4R, NPY4R, MC3R SLC1A3 289/4885SLC1A2 248/4885SLC1A1 182/4885
US-12590123-B2 Compounds and methods for treating cancer, viral infections, and allergic conditions TMPRSS2, TMPRSS4, F2RL3 SLC1A3 3992/4885SLC1A2 4216/4885SLC1A1 3295/4885
US-20120121623-A1 NOVEL ANTIPATHOGENIC PEPTIDES MAVS, VIP, ZC3HAV1 SLC1A3 3406/4885SLC1A2 4492/4885SLC1A1 3574/4885
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS THRB, MC1R, MC5R SLC1A3 348/4885SLC1A2 208/4885SLC1A1 244/4885
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus CTH, VIP, CXCL10 SLC1A3 404/4885SLC1A2 1464/4885SLC1A1 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.